Indian pharmaceutical company Bharat Biotech has said that a booster shot of its Covaxin COVID-19 vaccine administered six months after the last of two doses neutralises both the Omicron and Delta variants of COVID-19, Reuters news agency reported on Wednesday.

This study was conducted at the Emory Vaccine Centre in Atlanta, US, based on blood serum collected from 13 individuals, 28 days after their booster shot. It was sponsored by Bharat Biotech's partner Ocugen Inc (Nasdaq:OCGN).

In a statement, Bharat Biotech said: "The neutralisation activity of Covaxin-boosted sera was comparable to what has been observed in mRNA vaccine-boosted sera against the Omicron variant. More than 90% of all individuals boosted with Covaxin showed neutralising antibodies."

Covaxin, India's first domestically developed COVID-19 vaccine, received a WHO emergency-use listing late in 2021.